PayerTalkCE™ Presents: Advancing Equity: Pediatric Atopic Dermatitis Management in Managed Care

Learn About:

The experiences of pediatric patients and their caregivers in managing moderate-to-severe AD
Evidence-based treatment recommendations in pediatric AD
Collaborative strategies for the implementation of equitable drug coverage policies for pediatric AD treatments

Expert Faculty Presenters:


	Gary M. Owens, MD President Gary Owens Associates, Inc. Click here for biography

	Joy Wan, MD, MSCE Assistant Professor of Dermatology John Hopkins University School of Medicine Click here for biography

Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.

Statement of Need/Program Overview
An understanding of the overall burden of atopic dermatitis in children and recommended treatments that can empower managed care, specialty pharmacy, and other payer decision makers to implement health care benefit policy strategies that will enhance optimal treatment outcomes.

Educational Objectives
After completing this activity, the participant should be better able to:

Examine the experiences of pediatric patients and their caregivers in managing moderate-to-severe AD
Outline evidence-based treatment recommendations in pediatric AD
Explore collaborative strategies for the implementation of equitable drug coverage policies for pediatric AD treatments

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), the National Eczema Association (NEA) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-205-L01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Working Group Members/Planners*	*Reported Financial Relationship*
Gary M. Owens, MD	Consultant/Advisor/Speaker: Sanofi, Regeneron, Incyte, Baxter, CyRx, BD, Sage Therapeutics.
Joy Wan, MD, MSCE	Consultant/Advisor/Speaker: Janssen Researcher: Pfizer Data Monitoring Committee Member: Sun Pharmaceuticals

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

*Name of Content Manager*	*Reported Financial Relationship*
NEA Content Managers	No financial relationships to disclose.
PACE Content Managers	No financial relationships to disclose.
Impact Education, LLC Staff	No financial relationships to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.